The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
27155464 |
35 |
Part-1: Design, synthesis and biological evaluation of novel bromo-pyrimidine analogs as tyrosine kinase inhibitors. |
Rallis India |
27348537 |
60 |
Discovery of 3-(5'-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation. |
East China University of Science & Technology |
27010810 |
24 |
Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors. |
Oribase Pharma |
27011159 |
97 |
Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells. |
Experimental Therapeutics Centre |
26451772 |
42 |
Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine. |
First Affiliated Hospital of Xi'An Jiaotong University |
26298495 |
20 |
Expanding the structural diversity of Bcr-Abl inhibitors: Hybrid molecules based on GNF-2 and Imatinib. |
Xi'An Jiaotong University |
26231079 |
26 |
Synthesis and biological evaluation of novel aromatic-heterocyclic biphenyls as potent anti-leukemia agents. |
Xi'An Jiaotong University |
26195136 |
32 |
Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant. |
Guangzhou Institutes of Biomedicine and Health |
24280068 |
4 |
Imatinib analogs as potential agents for PET imaging of Bcr-Abl and c-KIT expression at a kinase level. |
The University of Texas M.D. Anderson Cancer Center |
23611771 |
8 |
The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588. |
Novartis Institutes For Biomedical Research |
23538233 |
16 |
Design, synthesis and biological activities of Nilotinib derivates as antitumor agents. |
Xi'An Jiaotong University |
23473682 |
69 |
BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives. |
The First People'S Hospital of Hangzhou |
23301767 |
154 |
Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities. |
University of Nottingham |
23088644 |
39 |
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)¿isoleucine(315) mutant. |
Chinese Academy of Sciences |
15975507 |
13 |
Features of selective kinase inhibitors. |
University of California San Francisco |
19610618 |
41 |
Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. |
University of South Florida |
16678414 |
25 |
3-Benzimidazol-2-yl-1H-indazoles as potent c-ABL inhibitors. |
Chiron |
16686543 |
44 |
Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. |
Universit£ |
21376587 |
15 |
Hybrid compounds as new Bcr/Abl inhibitors. |
Chinese Academy of Sciences |
20828158 |
92 |
Expanding the diversity of allosteric bcr-abl inhibitors. |
Harvard Medical School |
20817538 |
16 |
Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. |
Novartis Institutes For Biomedical Research |
20188579 |
42 |
Design, synthesis and evaluation of (E)-alpha-benzylthio chalcones as novel inhibitors of BCR-ABL kinase. |
Temple University |
16415863 |
2 |
Allosteric inhibitors of Bcr-abl-dependent cell proliferation. |
Genomics Institute of The Novartis Research Foundation |
20166671 |
85 |
Selectively nonselective kinase inhibition: striking the right balance. |
Schering-Plough |
16970400 |
14 |
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling. |
University of Milano-Bicocca |
16722630 |
100 |
Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. |
University of Regensburg |
16451066 |
58 |
Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase. |
Chembridge Research Laboratories and Chembridge |
15615512 |
21 |
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
32292564 |
138 |
Efficacy and Tolerability of Pyrazolo[1,5- |
The Genomics Institute of The Novartis Research Foundation |
26844689 |
22 |
Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions. |
Chinese Academy of Sciences |
31699612 |
15 |
Structure-based analysis and biological characterization of imatinib derivatives reveal insights towards the inhibition of wild-type BCR-ABL and its mutants. |
Peking Union Medical College and Chinese Academy of Medical Sciences |
31274316 |
9 |
Kinase Atlas: Druggability Analysis of Potential Allosteric Sites in Kinases. |
University of California |
30317026 |
23 |
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia. |
Chinese Academy of Sciences |
29617135 |
16 |
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361). |
Athenex |
31185413 |
45 |
Discovery of novel Bcr-Abl |
Xi'An Jiaotong University |
32184973 |
105 |
Design and Optimization of 3'-(Imidazo[1,2- |
Jinan University |
26562217 |
38 |
Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase. |
University of Southern California |
25464886 |
25 |
Discovery of novel Bcr-Abl inhibitors targeting myristoyl pocket and ATP site. |
Xi'An Jiaotong University |
29775937 |
52 |
Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors. |
Chinese Academy of Sciences |
29945794 |
193 |
ROCK inhibitors 2. Improving potency, selectivity and solubility through the application of rationally designed solubilizing groups. |
Vertex Pharmaceuticals |
29407977 |
30 |
Effects of rigidity on the selectivity of protein kinase inhibitors. |
University of Southern California |
29395973 |
1 |
Design and synthesis of novel dasatinib derivatives as inhibitors of leukemia stem cells. |
Tianjin International Joint Academy of Biomedicine |
29752185 |
1 |
Brain penetrant kinase inhibitors: Learning from kinase neuroscience discovery. |
Eli Lilly |
28337325 |
131 |
Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. |
Jinan University |
28626524 |
4 |
F-NMR-Based Dual-Site Reporter Assay for the Discovery and Distinction of Catalytic and Allosteric Kinase Inhibitors. |
Novartis Institutes For Biomedical Research |